Welcome to Evogene's Fourth Quarter 2025 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded, March 5, 2026. Before we begin, I would like to caution that ...
The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share ...
Live Updates The 3 Biggest Takeaways from Broadcom's Wild Q1 Conference Call Yesterday Broadcom’s (AVGO) conference call is winding down, and we’ll also be winding down updates on this live blog. Once ...
Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming ...
Evolus, Inc. ( EOLS) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Fourth Quarter and Full Year 2025 Earnings Conference ...
Compugen Ltd. (NASDAQ: CGEN) Q4 2025 Earnings Call Transcript March 2, 2026 Compugen Ltd. beats earnings expectations. Reported EPS is $0.6, expectations were $0.05.
Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant ...
Strategic leadership changes -- Eran Ophir became CEO in September 2025, with Anat Cohen-Dayag transitioning to Executive Chair to enhance operational focus and strategic continuity.
Rural Revitalization, High-Quality Development, Industrial Integration, Rural Governance, Jiangsu Pathways Share and Cite: Fang, W. (2026) Research on the Pathways for Jiangsu Province to ...
Powerplex, aka Scott Duvall, is the electrifying star of the latest Invincible VS gameplay trailer. This 3v3 tag fighting ...
Zhao, J. and Xu, J. (2026) The Impact of Moral Distress on Nurses Work Alienation in Third Grade Class-A Hospital in Wuhan. Yangtze Medicine, 10, 1-9. doi: 10.4236/ym.2026.101001 .